MedPath

Safety and Efficacy of Selective Intra-Arterial Cooling Infusion Combined With EVT in Acute Ischemic Stroke

Not Applicable
Recruiting
Conditions
Acute Ischemic Stroke
Hypothermia
Interventions
Procedure: Selective Intra-arterial Cooling Infusion (IA-SCI)
Registration Number
NCT06485427
Lead Sponsor
Beijing Shijitan Hospital, Capital Medical University
Brief Summary

This is a multicenter, randomized, controlled, subject- and assessor-blinded clinical trial. The research objective is to evaluate the safety and efficacy of selective intra-arterial cooling infusion combined with endovascular therapy in the treatment of acute anterior circulation large vessel occlusion stroke. This trial aims to enroll 258 subjects. Patients assigned to the control group will receive best medical management (BMM) and endovascular therapy (EVT). Those in the selective intra-arterial cooling infusion group (IA-SCI group) will undergo selective intra-arterial cold saline infusion, in addition to BMM and EVT. Subjects will be interviewed face-to-face at randomization, 24±6 hours, 48±6 hours after randomization, 7±2 days/discharge. Telephone interviews/ face-to face interviews will be performed at 30±3 days and 90±7 days after randomization. The primary outcome is the distribution of Modified Rankin Score at 90±7days after randomization.

Detailed Description

Acute ischemic stroke (AIS) is the leading cause of death and disability in China. Randomized trials involving patients with acute stroke due to large-artery occlusion in the anterior circulation have shown a benefit of endovascular therapy (EVT). Although EVT achieves successful recanalization in over 80% of patients, only 46% of patients are functionally independent (mRS 0-2) after the intervention . Therefore, new ancillary therapeutic strategies are needed to further improve the clinical outcomes.

Therapeutic systemic hypothermia has been suggested to be one such potential approach offering a viable neuroprotective strategy. However, several adverse events associated with the systematic hypothermia treatment have been reported. Those offset the therapeutic benefits of systemic hypothermia. Selective intra-arterial cooling infusion (IA-SCI) targets precisely the ischemic brain tissue with the infusion of hypothermic solutions. This approach induces a state of mild hypothermia in the ischemic region without causing substantial drops in core body temperature, thereby minimizing the incidence of systemic side effects. Previous studies have shown that IA-SCI with cold saline combined with EVT in AIS is safe and feasible.

Hence, the investigators design a multicenter, randomized, controlled, subject- and assessor-blinded clinical trial. The objective of this trial is to further explore the safety and efficacy of selective intra-arterial cooling infusion combined with EVT in the treatment of acute anterior circulation large vessel occlusion stroke, and 258 subjects will be enrolled. Subjects assigned to the control group will receive best medical management (BMM) and endovascular therapy (EVT). Those in the selective intra-arterial cooling infusion group (IA-SCI group) will undergo selective intra-arterial cold saline infusion, in addition to BMM and EVT. Subjects will be interviewed face-to-face at randomization, 24±6 hours, 48±6 hours after randomization, 7±2 days/discharge. Telephone interviews/ face-to face interviews will be performed at 30±3 days and 90±7 days after randomization. The primary outcome is the distribution of Modified Rankin Score at 90±7days after randomization.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
258
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
IA-SCI groupSelective Intra-arterial Cooling Infusion (IA-SCI)Subjects randomized to the IA-SCI group will receive selective intra-arterial cooling infusion plus BMM and EVT.
Primary Outcome Measures
NameTimeMethod
Distribution of Modified Rankin scale90 ±7days

the distribution of Modified Rankin scale (mRS) \[ranging from 0 (normal) to 6 (death)\]

Secondary Outcome Measures
NameTimeMethod
Percentage of functional independence (mRS scale 0-2)90 ±7days

the percentage of mRS scale 0-2 (Modified Rankin scale \[ranging from 0 (normal) to 6 (death)\])

Percentage of favorable outcome (mRS scale 0-1)90 ±7days

the percentage of mRS scale 0-1(Modified Rankin scale \[ranging from 0 (normal) to 6 (death)\])

Final infarction volume7±2 days/discharge

A plain computed tomography (CT) scan will be performed. The infarct area is defined as the low-density area. The infarct area is semi-automatically delineated by the software. The infarct volume= the sum of the infarct area of each layer × layer thickness (5mm).

The changes of infarction volume7±2 days/discharge

the changes of infarction volume between baseline and 7±2 days/discharge assessed by CT

National Institute of Health stroke scale (NIHSS) score7±2 days/discharge

National Institute of Health stroke scale (NIHSS) score \[ranging from 0 to 42 points, with higher numbers indicating greater severity\]

Barthel Index score7±2 days/discharge

the Barthel Index score \[the sum of the score ranging from 0 to 100, with 100 being the most independent level of function\]

Rapid neurologic improvement24±12 hours

Rapid neurologic improvement is defined as a reduction of ≥8 on the National Institutes of Health Stroke Scale \[ranging from 0 to 42 points, with higher numbers indicating greater severity\] or National Institutes of Health Stroke Scale zero to one 24 hours after thrombectomy.

Changes in ipsilateral tympanic membrane temperatureduring surgery.

Changes in ipsilateral tympanic membrane temperature before and after intra-arterial cooling infusion in the IA-SCI group.

Power spectral density (PSD) assessed by continuous electroencephalogram (EEG)within 7±2 days/discharge

PSD is estimated using Welch's periodogram from EEG.

(delta+theta)/(alpha+beta) power ratio (DTABR) assessed by continuous electroencephalogram (EEG)within 7±2 days/discharge

DTABR is calculated using the absolute power for each of spectral band on EEG.

Delta/alpha power ratio (DAR) assessed by continuous electroencephalogram (EEG)within 7±2 days/discharge

DAR is calculated using the absolute power for each of spectral band on EEG.

Brain symmetry index (BSI) assessed by continuous electroencephalogram (EEG)within 7±2 days/discharge

BSI is calculated using the power values from both left and right hemispheres from EEG.

Symptomatic intracranial hemorrhage24±12 hours

Defined as any intracranial hemorrhage accompanied by neurological deterioration (NIHSS score increased by more than 4 points compared with the lowest NIHSS score at enrollment or during hospitalization) or death caused by any cerebral hemorrhage according to the ECASS III study.

Any intracranial hemorrhage24±12 hours

any intracranial hemorrhage assessed by CT

Intracranial arterial vasospasm after IA-SCI that requires further therapeutic intervention.during operation

Patients with vasospasm confirmed by DSA and requiring further therapeutic intervention

Proportion of subjects with pulmonary, urinary tract infection and gastroenteritis7±2 days/discharge

the proportion of patients with pulmonary, urinary tract infection and gastroenteritis according to the Centers for Disease Control and Prevention (CDC)/ National Healthcare Safety Network (NHSN) criteria.

Proportion of subjects with coagulation abnormalities24±12 hours

Defined as abnormal coagulation function

Proportion of subjects with electrolyte imbalance24±12 hours

Defined as any abnormal findings, including hypernatremia, hyponatremia, hyperkalemia, or hypokalemia.

Changes in core temperature before and after intra-arterial cooling infusion in the IA-SCI group.During operation

Changes in rectal temperature before and after intra-arterial cooling infusion in the IA-SCI group.

any death90±7 days

any death

other AE/SAE90±7 days

other adverse events/ serious adverse events

Trial Locations

Locations (9)

The Second Hospital and Clinical Medical School, Lanzhou University

🇨🇳

Lanzhou, Gan Su, China

Department of Neurosurgery, Nanshi Hospital of Nanyang

🇨🇳

Nanyang, He Nan, China

The Affiliated Hospital of Xuzhou Medical University

🇨🇳

Xuzhou, Jiang Su, China

Peking University Internation Hospital

🇨🇳

Beijing, China

Beijing Shijitan Hospital, Capital Medical University

🇨🇳

Beijing, China

967 Hospital of the Joint Logistics Support Force of PLA

🇨🇳

Dalian, China

Dalian Municipal Central Hospital

🇨🇳

Dalian, China

The First Affiliated Hospital of Harbin Medical University

🇨🇳

Ha'erbin, China

Affiliated Hospital of Inner Mongolia University for the Nationalities

🇨🇳

Tongliao, China

© Copyright 2025. All Rights Reserved by MedPath